Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Tantawy, Shady I. [1 ]
Timofeeva, Natalia [1 ]
Fujiwara, Hitomi [2 ]
Hatakeyama, Mariko [2 ]
Herrera, Breana [1 ]
Loza, Lizbeth [1 ]
Asami, Tokiko [2 ]
Ohmoto, Hiroshi [2 ]
Miyamoto, Kyoko [3 ]
Nishioka, Yu [2 ]
Arimura, Akinori [3 ]
Sawa, Masaaki [2 ]
Jain, Nitin [4 ]
Gandhi, Varsha [1 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Carna Biosci Inc, Kobe, Hyogo, Japan
[3] CarnaBio USA Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189659
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
    Jain, Nitin
    D'Olimpio, James
    Gillis-Smith, Andew
    Lee, Seung Tae
    Shah, Nirav N.
    Pinilla-Ibarz, Javier
    Coombs, Catherine C.
    Barrientos, Jacqueline C.
    Ma, Shuo
    Sawa, Masaaki
    Miyamoto, Kyoko
    Arimura, Akinori
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2023, 142
  • [2] Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase
    Kawahata, Wataru
    Asami, Tokiko
    Kiyoi, Takao
    Irie, Takayuki
    Kashimoto, Shigeki
    Furuichi, Hatsuo
    Sawa, Masaaki
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14129 - 14141
  • [3] AS-1763: a highly potent, noncovalent and next generation BTK inhibitor for the treatment of patients with B-cell malignancies having C481S mutation in BTK
    Kawahata, Wataru
    Asami, Tokiko
    Kiyoi, Takao
    Irie, Takayuki
    Kashimoto, Shigeki
    Furuichi, Hatsuo
    Sawa, Masaaki
    CANCER RESEARCH, 2022, 82 (12)
  • [4] An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia
    Geethakumari, Praveen Ramakrishnan
    Awan, Farrukh
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1039 - 1046
  • [5] Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
    Jebaraj, Billy Michael Chelliah
    Mueller, Annika
    Dheenadayalan, Rashmi Priyadharshini
    Endres, Sascha
    Roessner, Philipp M.
    Seyfried, Felix
    Walliser, Claudia
    Wist, Martin
    Qi, Jialei
    Tausch, Eugen
    Mertens, Daniel
    Fox, Judith A.
    Debatin, Klaus-Michael
    Meyer, Luder Hinrich
    Taverna, Pietro
    Seiffert, Martina
    Gierschik, Peter
    Stilgenbauer, Stephan
    BLOOD, 2022, 139 (06) : 859 - 875
  • [6] The PKCß inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant chronic lymphocytic leukemia
    Gordon, Britten
    Muhowski, Elizabeth
    Ravikrishnan, Janani
    Thangavadivel, Shanmugapriya
    Benrashid, Samon
    He, Alexander
    Misra, Shrilekha
    Lai, Tzung-Huei
    Marr, Alexander
    Walker, Brandi
    Perry, Elizabeth
    Grieselhuber, Nicole
    Rogers, Kerry
    Blachly, James
    Kittai, Adam
    Bhat, Seema
    Byrd, John
    Niesman, Michael
    Zhang, Kai
    Sampath, Deepa
    Woyach, Jennifer
    LEUKEMIA & LYMPHOMA, 2023, 64 : S37 - S38
  • [7] Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
    Mato, Anthony R.
    Woyach, Jennifer A.
    Brown, Jennifer R.
    Ghia, Paolo
    Patel, Krish
    Eyre, Toby A.
    Munir, Talha
    Lech-Maranda, Ewa
    Lamanna, Nicole
    Tam, Constantine S.
    Shah, Nirav N.
    Coombs, Catherine C.
    Ujjani, Chaitra S.
    Fakhri, Bita
    Cheah, Chan Y.
    Patel, Manish R.
    Alencar, Alvaro J.
    Cohen, Jonathon B.
    Gerson, James N.
    Flinn, Ian W.
    Ma, Shuo
    Jagadeesh, Deepa
    Rhodes, Joanna M.
    Hernandez-Ilizaliturri, Francisco
    Zinzani, Pier L.
    Seymour, John F.
    Balbas, Minna
    Nair, Binoj
    Abada, Paolo
    Wang, Chunxiao
    Ruppert, Amy S.
    Wang, Denise
    Tsai, Donald E.
    Wierda, William G.
    Jurczak, Wojciech
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (01): : 33 - 44
  • [8] The PKC-ß Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia
    Gordon, Britten
    Muhowski, Elizabeth
    Ravikrishnan, Janani
    Thangavadivel, Shanmugapriya
    Benrashid, Samon
    He, Alexander
    Misra, Shrilekha
    Lai, Tzung-Huei
    Marr, Alexander
    Yu, Lianbo
    Walker, Brandi
    Perry, Elizabeth
    Grieselhuber, Nicole R.
    Rogers, Kerry A.
    Blachly, James S.
    Kittai, Adam S.
    Bhat, Seema A.
    Byrd, John C.
    Niesman, Michael
    Zhang, Kai
    Sampath, Deepa
    Woyach, Jennifer A.
    BLOOD, 2023, 142
  • [9] Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
    Li, Yan
    Ramirez-Valle, Francisco
    Xue, Yongjun
    Ventura, Judith I.
    Gouedard, Olivier
    Mei, Jay
    Takeshita, Kenichi
    Palmisano, Maria
    Zhou, Simon
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (10): : 1279 - 1289
  • [10] BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
    Desikan, Sai Prasad
    Venugopal, Sangeetha
    Ferrajoli, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (05) : 403 - 409
12345